ALIBABA-CLOUD
Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, started its annual Apsara Conference today by announcing the launch of ModelScope, an open-source Model-as-a-Service (MaaS) platform that comes with hundreds of AI models, including large pre-trained models for global developers and researchers. During its flagship conference, the global leading cloud provider also introduced a range of serverless database products and upgraded its integrated data analytics and intelligent computing platform to help customers further achieve business innovation through cloud technologies.
"Cloud computing has given rise to a fundamental revolution in the way computing resources are organized, produced and put to commercial use while shifting the paradigm of software development and speeding up the integration of the cloud and endpoint terminals," Jeff Zhang, President of Alibaba Cloud Intelligence, "As more customers are speeding up with their cloud adoption, we have been upgrading our cloud-based resources, services and tools to become serverless, more intelligent and digitalized in order to lower the barrier for companies to adopt new technology and capture more opportunities in the cloud era."
MaaS to create transparent and inclusive technology community
The ModelScope platform is today launched with over 300 ready-to-deploy AI models developed by Alibaba DAMO Academy ("DAMO"), Alibaba's global research initiative, in the past five years. These models cover various fields from computer vision to natural language processing (NLP) and audio. The platform also includes more than 150 state-of-the-art (SOTA) models, which are recognized globally as the best in their respective fields for achieving the results in a given task.
Also made available on the platform are Alibaba’s proprietary large pre-trained models such as Tongyi, which is capable of turning text into image with five billion parameters, and OFA (One-For-All), a six billion-parameter pre-trained model that excels at cross-modal tasks such as image captioning and visual question answering. Independent developers have also contributed dozens of models to the open-source platform to date.
As an open-source community, ModelScope aims to make developing and running AI models easier and more cost effective. Developers and researchers can simply test the models online for free and get the results of their tests within minutes. They can also develop customized AI application by fine-tuning existing models, and run the models online backed by Alibaba Cloud, or deploy them on other cloud platforms or in a local setting.
The launch underscores DAMO’s ongoing efforts and commitment to promote transparent and inclusive technology by reducing the threshold for building and running AI models, enabling universities and smaller companies to easily use AI for their research and in their business respectively. The community is expected to grow further with more quality models available on the platform from DAMO, partners from research institutes and third-party developers in the near future.
New and upgraded solutions to increase computing efficiency
Staying ahead of the emerging trend of serverless software development, Alibaba Cloud is making its key cloud products serverless to enable customers to concentrate on product deployment and development without worrying about managing servers and infrastructure. Essentially, Alibaba Cloud’s updated products focus on turning computing power into an on-demand capability for users.
Examples of these are the cloud native database PolarDB, the cloud-native data warehouse AnalyticDB (ADB) and ApsaraDB for Relational Database Service (RDS). Leveraging Alibaba Cloud’s serverless technologies, customers can enjoy automatic scaling with extreme elasticity based on actual workloads and a pay-as-you-go billing model to reduce costs. The automatic elastic scaling time on demands can be as little as one second. The use of updated database products can help businesses in the internet industry reduce their costs by 50%, on average, compared to using traditional ones. Currently, Alibaba Cloud has more than 20 serverless key products in total and is adding more product categories to become serverless.
Alibaba Cloud also upgraded its ODPS (Open Data Platform and Services), a self-developed integrated data analytics and intelligent computing platform, to provide companies with diversified data processing and analytics services. The platform can handle both online and offline data simultaneously in one system, providing businesses dealing with complex workloads with analytics for business decision-making with reduced cost and increased efficiency.
ODPS has refreshed global records for big data performance, according to recent results from the Transaction Processing Performance Council (TPC), an industry council that sets the standards for transaction processing and database benchmarking. Evaluated based on a 100 TB data benchmark, the performance of ODPS Maxcompute Cluster attained the top score for the sixth consecutive year. ODPS Hologres Cluster also shown a record-breaking result in the TPC-H 30000GB decision support benchmark test.
To drive workload collaboration between cloud and local hardware, Alibaba Cloud has announced the launch of the Wuying Architecture with a showcase on its applications on the Wuying Cloudbook. The Cloudbook with dedicated Architecture is designed to help users access unlimited computing power on the cloud in a more secure and agile manner while supporting collaboration and flexibility at a workplace.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com) is the digital technology and intelligence backbone of Alibaba Group. It offers a complete suite of cloud services to customers worldwide, including elastic computing, database, storage, network virtualization services, large-scale computing, security, management and application services, big data analytics, a machine learning platform and IoT services. Alibaba maintained its position as the third leading public cloud IaaS service provider globally since 2018, according to IDC. Alibaba is the world’s third leading and Asia Pacific’s leading IaaS provider by revenue in U.S. dollars since 2018, according to Gartner.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102006197/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom